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Abstract
Background: For many years smoking has been the major threat to public health in developed countries.
However, smoking prevalence has declined over a period when adiposity has increased. The aim of this study
was to determine whether adiposity now accounts for more deaths than smoking in the general population
as a whole or sub-groups of it.
Methods: This is a comparative risk assessment study using Health Surveys for England and Scottish Health
Surveys from 2003 to 2017. Annual prevalence of overweight, obesity, current and former smoking were
obtained and combined using population-based weights. Sex-specific risk ratios for all-cause mortality were
obtained from the most recently published meta-analyses. Population attributable fractions across yeas were
then estimated.
Findings: Overall, deaths attributable to current/former smoking declined from 23.1% (95% CI 20.6–25.8%) in
2003 to 19.4% (95% CI 17.3–21.6%) in 2017, whilst those attributable to adiposity (overweight or obesity)
increased from 17.9% (95% CI 17.3–18.4%) in 2003 to 23.1% (95% CI 22.3–23.8%) in 2017 with cross-over
occurring in 2013. Cross-over occurred earlier in men (2011) than women (2014). It occurred in 2006 for those
aged over 65 years of age and in 2012 for those aged 45–64 years. Below 45 years, smoking remained the
larger contributor to mortality.
Interpretation: Adiposity now accounts for more deaths in England and Scotland than smoking among
people in middle- and old-age. National strategies to address adiposity should be a public health priority.
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Background
For several decades, smoking has been a major target of
public health interventions, because it made the largest
contribution to avoidable deaths [1–3]. In 2004, the
World Health Organization [4] calculated that smoking
was the top ranked risk factor for all high-income coun-
tries accounting for 18% of all deaths, including from
lung cancer and cardiovascular disease [5], in contrast to
adiposity, which was ranked third and accounted for 8%,
including from cardiovascular disease and diabetes melli-
tus [6]. In 2005, 109,164 (19%) deaths in the United
Kingdom were attributable to smoking [7].
In common with other developed countries, the preva-
lence of smoking has fallen in the United Kingdom; from
24% in 2005 to 17% in 2017 [8]. Over the same period,
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the prevalence of obesity has increased from 23 to 29%
[9]. Whilst smoking is still the largest contributor to
cancers overall – 15% of all new cancers in 2015 were
attributed to smoking compared with 6% attributed to
adiposity [10] – adiposity now exceeds smoking in terms
of its contribution to a number of specific cancers in-
cluding bowel, kidney, ovary, and liver [11]. Meanwhile,
the longstanding decrease in cardiovascular mortality
across high-income countries has slowed in recent years,
and may even start to increase in North America, with
the increasing prevalence of obesity being postulated as
a cause [12].
To our knowledge, there are no recent studies that
have compared the relative health burden of smoking
and adiposity in the UK population as well as in popula-
tion subgroups. The aim of this study was to determine
whether adiposity now exceeds smoking in terms of its
contribution to all-cause deaths, either in the population
of England and Scotland as a whole, or within specific
age, sex and socioeconomic sub-groups of it.
Methods
Prevalence of adiposity and smoking
Annual prevalence of overweight, obesity, current and
former smoking were obtained from the Health Surveys
for England (HSE) and Scottish Health Surveys (SHeS).
These household surveys were conducted to monitor the
health of the general population in England and
Scotland. The surveys used two-stage stratified random
sampling. A random sample of area-based primary sam-
pling units (based on postcode sectors) were drawn,
from which a random sample of postal addresses were
selected. All adults (≥16 years of age) and up to 4 chil-
dren (< 16 years of age) in the selected households were
invited to participate the health surveys. Household
response rates ranged from 58 to 73% and individual re-
sponse rates ranged from 54 to 66% with a general de-
clining trend over 2003 to 2017. People who lived in
institutions were excluded from the surveys. The HSE
was conducted every year from 2003 to 2017. The SHeS
was conducted in 2003, and then annually from 2008 to
2017. The prevalence in Scotland in the missing years
were interpolated using cubic splines [13] fitted on the
available Scottish prevalence data.
Data were collected via face-to-face interviews (e.g.
sociodemographic information and smoking status).
Physical measurements (e.g. body height and weight)
were conducted by survey administrators in all years for
HES and since 2012 for SHeS. Prior to that, physical
measurements in SHeS were conducted in a follow-up
visit by nurses. Smoking status was self-reported using
the same question prompt across years and was cate-
gorised into never, former and current smoker. Height,
to the nearest 1 mm, and weight, to the nearest 0.1 kg,
were measured by trained interviewers or nurses using
standardised stadiometers and scales. Body mass index
(BMI) was calculated using the formula (weight in kg)
/ (height in m)2, and was used to classify participants
into: non-overweight or obese (<25 kg/m2), overweight
(25 to <30 kg/m2), class I obese (30 to <35 kg/m2),
class II obese (35 to <40 kg/m2) and class III obese
(≥40 kg/m2).
In this study, participants aged under 16 years were ex-
cluded because there are no reliable risk ratio estimates.
Only population representative samples from the surveys
were included and boost samples targeting a subset of
the population were excluded. Survey weightings were
used to estimate the population prevalence in England
and Scotland separately. These were combined, using
weightings based on the annual population estimates in
the two countries, to produce annual prevalence for
England and Scotland combined [14].
Risk ratios of adiposity and smoking
Risk ratios (RRs) were used for the estimation of popula-
tion attributable fraction. RR is the ratio of absolute risk
between exposed (e.g. smoker, BMI > =30) and reference
(e.g. never smoker, BMI < 25) groups, and is a measure
of relative risk. A systematic literature search was con-
ducted, using PubMed, to determine the RRs of dying
from overweight, obese, current and former smoking
using these keywords: (‘all-cause mortality’ OR ‘total
mortality’) AND ((‘smoking’ OR ‘smoke’ OR ‘cigarette’)
OR (‘overweight’ OR ‘obesity’ OR ‘BMI’ OR ‘body mass
index’ OR ‘excess weight’)) AND ‘meta-analysis’ AND
‘prospective’. The RRs, and confidence intervals (CIs),
reported in the most recent meta-analysis were extracted
for this study because they cover the greatest number of
studies and overlap with the study period. Because sex is
commonly an effect modifier, sex-specific RRs were
used. This meta-analysis for smoking included 17 stud-
ies; all studies adjusted for age and sex, and 9 also ad-
justed for blood pressure, 9 for alcohol consumption,
and 6 for physical activity. The pooled RRs (95% CIs) ap-
plied to current smoking in women and men were 1.80
(1.59–2.04) and 1.90 (1.72–2.10) respectively and to
former smoking were 1.32 (1.23–1.40) and 1.34 (1.27–
1.40) respectively [15]. The meta-analysis for adiposity
included 157 and 141 studies for men and women re-
spectively and reported age and sex adjusted hazard ra-
tios (HRs) among never-smokers without pre-existing
chronic conditions [16]. For women, the pooled HRs
(95% CI) for overweight, obese I, II and III were: 1.08
(1.07–1.10), 1.37 (1.34–1.40), 1.86 (1.79–1.93), and 2.73
(2.57–2.91). The respective values for men were: 1.12
(1.11–1.13), 1.70 (1.63–1.77), 2.68 (2.54–2.83), and 4.24
(3.77–4.76) [16]. HRs are the ratios of instantaneous
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incidence rate and were converted into RRs using the
formula described elsewhere [17].
Statistical analyses
The population attributable fraction (PAF) for each risk fac-





, where pi was the prevalence and RRi was the
risk ratios of the ith category of the risk factor [18]. PAF indi-
cates the proportions of deaths in the population that were
attributable to the risk factor. People who never smoke and
people with BMI <25 kg/m2 were the reference groups for
smoking and adiposity respectively. The risk attributed by
underweight (BMI <18.5 kg/m2) was omitted in this study.
The confidence interval for the PAF was calculated using
1000 bootstrap repetitions based on the variances of both
prevalence and RRs [18]. Bootstrapping using 2000 repeti-
tions resulted in very similar results. The PAFs for each year
were then smoothed and plotted using local polynomial re-
gression [19]. Local polynomial regression is a nonparametric
technique to smooth a trend line.
Because the RRs for smoking were extracted from a
meta-analysis of older adults and might not be applic-
able to younger people, we also estimated the HRs of
former and current smoking using UK Biobank data. UK
Biobank is a prospective cohort study of over 500,000
people in England, Scotland and Wales. Death was
ascertained using linked data up to May 2020 with a me-
dian follow-up of 12 years. A Cox proportional hazard
model was used to estimate the HRs of former and
current smoking by sex adjusting for age, sex, ethnicity,
deprivation, physical activity, and diet. These HRs were
then converted into RRs and PAFs were estimated. All
analyses were conducted using R statistical software ver-
sion 3.5.3 and the packages akima and pifpaf.
Results
The study population comprised 192,239 participants:
136,171 from the HSE and 56,068 from the SHeS
(Table 1). Women accounted for 56% of participants
and the mean (SD) age was 49.9 (18.6) years. More than
two-thirds of participants continued full-time education
beyond 16 years of age. The mean (SD) BMI was 27.4
(5.3) kg/m2, and around half of the participants were
current or former smokers.
The annual prevalence of overweight, obesity, current
and former smoking is consistent with previous reports
in England and Scotland (Supplementary Table 1). The
percentage of the population with obesity (including
Classes I to III) increased steadily from 22.8% in 2003 to
29.1% in 2017. The trend occurred across all age, sex
and education sub-groups, but the greatest increases
were observed among participants aged 45–64 years
(from 27.6 to 35.4%), women (from 23.6 to 30.3%), and
those who continued full-time education beyond 16
years of age (from 21.1 to 28.9%). Over the same period,
the prevalence of current smoker decreased from 26.2%
in 2003 to 18.3% in 2017. The largest decreases were ob-
served among participants aged 16–44 years (from 32.9
to 22.9%), women (from 24.9 to 16.4%), and those who
continued full-time education beyond 16 years of age
(from 26.2 to 17.3%).
The percentage of all deaths attributable to current or
former smoking declined from 23.1% (95% CI 20.6–
25.8%) in 2003 to 19.4% (95% CI 17.3–21.6%) in 2017,
whilst those attributable to adiposity (overweight or
obesity) increased from 17.9% (95% CI 17.3–18.4%) in
2003 to 23.1% (95% CI 22.3–23.8%) in 2017 (Fig. 1). The
contribution of adiposity exceeded that of smoking in
2013. In 2017, adiposity contributed to 3.7% more deaths
than smoking with non-overlapping confidence intervals.





N (%) N (%)
Year
2003–2007 50,194 (36.9) 8148 (14.5)
2008–2012 45,063 (33.1) 30,149 (53.8)
2013–2017 40,914 (30.0) 17,771 (31.7)
Sex
Female 75,591 (55.5) 31,462 (56.1)
Male 60,580 (44.5) 24,606 (43.9)
Age at assessment (years)
16–44 55,749 (40.9) 20,615 (36.8)
45–64 45,673 (33.5) 19,847 (35.4)
≥ 65 34,749 (25.5) 15,606 (27.8)
Age at leaving full-time education (years)
< 16 41,818 (30.8) 18,574 (33.2)
≥ 16 93,918 (69.2) 37,295 (66.8)
Body mass index (kg/m2)
< 18.5 1793 (1.5) 683 (1.5)
18.5–< 25.0 40,741 (34.8) 14,809 (31.6)
25.0–< 27.5 24,461 (20.9) 9626 (20.5)
27.5–< 30.0 19,631 (16.8) 8144 (17.4)
30.0–< 35.0 20,603 (17.6) 9208 (19.6)
35.0–< 40.0 6913 (5.9) 3193 (6.8)
≥ 40.0 2791 (2.4) 1232 (2.6)
Smoking
Current 28,722 (21.1) 13,375 (23.9)
Former 35,928 (26.4) 14,094 (25.1)
Never 71,521 (52.5) 28,599 (51.0)
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The general patterns were similar in men and women,
but the crossover date occurred earlier in men (2011)
than women (2014) (Fig. 2). In 2017, adiposity accounted
for 5.2% more deaths in men than smoking with non-
overlapping confidence intervals. In women, the differ-
ence was 2.2% with overlapping confidence intervals.
The temporal trends were more striking in older age-
groups. The crossover occurred in 2006 among partici-
pants ≥65 years of age compared with 2012 in those aged
45–64 years (Fig. 3). In 2017, adiposity accounted for
3.5% more deaths over 65 years of age than smoking
with non-overlapping confidence intervals. Among
Fig. 1 Percentage of all-cause deaths attributable to adiposity and smoking. Shaded areas are 95% confidence bands. Vertical dashed line
indicates cross-over
Fig. 2 Percentage of all-cause deaths attributable to adiposity and smoking by sex. Shaded areas are 95% confidence bands. Vertical dashed line
indicates cross-over
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participants below 45 years of age, smoking remained
the larger contributor to deaths over the whole study
period. However, the gap decreased dramatically. In
2003 smoking accounted for 10.7% more deaths than
adiposity but, by 2017, this had fallen to 2.4% with over-
lapping confidence intervals. The trend was more pro-
nounced among those who left school at or after 16
years of age than those before (Fig. 4). Unsmoothed esti-
mates of PAFs are shown in Supplementary Tables 2, 3,
4 and 5.
The HRs of former and current smoking among fe-
male participants in UK Biobank were estimated to be
1.16 (95% CI 1.08–1.24) and 2.27 (95% CI 2.06–2.49) re-
spectively. Those among male were 1.24 (95% CI 1.18–
1.31) and 2.19 (95% CI 2.05–2.34) respectively. The
PAFs estimated using these are shown in Supplementary
Figs. 1, 2, 3 and 4. The trends were the same as in the
main analyses with slightly delayed cross-overs. For ex-
ample, the contribution of adiposity to mortality
exceeded that of smoking in 2014, compared with 2013
in the main analysis.
Discussion
Principal findings
This study showed a steady increase in the percentage of
deaths attributable to adiposity in England and Scotland
over 15 years, and a steady decline in those attributable
to smoking over the same period. As a result, adiposity
has exceeded smoking as a contributor to deaths since
2014, and the difference has widened.
Whilst the overall trends were fairly consistent across
different sub-groups of the population, there were some
interesting differences in the timing and magnitude of
change. Among older age-groups, the crossover between
Fig. 3 Percentage of all-cause deaths attributable to adiposity and smoking by age group. Shaded areas are 95% confidence bands. Vertical
dashed line indicates cross-over
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smoking and adiposity occurred earlier and, therefore,
the difference in magnitude is now greater. The earlier
crossover in this sub-group reflects their lower preva-
lence of smoking and higher prevalence of overweight or
obese. The trend was also more pronounced in men
than women, in spite of men having a higher annual
prevalence of smoking than women, and a lower preva-
lence of obesity.8 9 This is largely due to obesity being
associated with a higher mortality risk ratio in men than
women [16] as well as more overweight men than
women; therefore the same increase in prevalence will
produce a greater impact on men.
Strengths and weaknesses of the study
In this study, the internal and external validity of the
PAF estimates were enhanced by the use of general
population representative data from England and
Scotland, and up-to-date risk ratio estimates obtained
from meta-analyses of prospective cohort studies. The
response rate of both surveys has reduced over time.
Any systematic error is likely to take the form of an in-
creasing healthy volunteer effect. Therefore, the
estimated PAFs may be underestimates. However, sys-
tematic differences in response on the basis of smoking
versus obesity are unlikely. Because cohort studies are
observational, causation cannot be assumed, and the es-
timates of risk may be affected by residual confounding.
The RRs we extracted for smoking were adjusted for age
and sex, and partially for blood pressure, physical activ-
ity, and alcohol consumption [15]; while those for adi-
posity were adjusted for age and sex among never-
smokers without pre-existing chronic diseases [16]. Be-
cause the effects of lifestyle factors on mortality are
mediated through chronic illnesses, the susceptibility to
confounding bias between the two sets of RRs should be
similar and therefore comparison between the PAFs
should be valid. The risk ratio for smoking was based on
a 2012 meta-analysis of smokers aged ≥60 years, which
may impact its generalisability to our study population
as RRs might be different for younger people. Nonethe-
less, our sensitivity analysis using UK Biobank data pro-
vided consistent conclusions. RRs were assumed to
remain constant over time and applicable to the UK
population even though they were based on studies from
various countries. The data from the HSE and SHeS
have shown that the median number of cigarettes per
day among current smokers has declined from 14.3 and
15.0 in 2003 to 10.0 and 11.3 in 2017 in England and
Scotland respectively. This indicates that if the RR of
smoking did change during the study, it would likely to
be slightly reduced, resulting in our study overestimating
the numbers of deaths attributable to smoking in the re-
cent years. The effect sizes of smoking between our se-
lected meta-analysis and studies from UK and Europe
were very similar [20], and those of adiposity were
slightly stronger in European studies [16]. These indi-
cates that our findings are likely to be a slight underesti-
mate of the increasing contribution of obesity. Smoking
deception can result in some current smokers misclassi-
fying themselves as former smokers but this is less com-
mon in general population cohorts than smoking-related
disease cohorts [21]. BMI is an imperfect measure of
adiposity; especially in younger men with high lean body
mass. These limitations in the measurement of expo-
sures apply to all study years; therefore, temporal bias is
unlikely. Our study was confined to all-cause mortality
Fig. 4 Percentage of all-cause deaths attributable to adiposity and smoking by age at completion of full-time education. Shaded areas are 95%
confidence bands. Vertical dashed line indicates cross-over
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and the findings will not necessarily apply to other
disease-specific outcomes where the relative contribu-
tion of the two risk factors may be different.
Strengths and weaknesses in relation to other studies
Previous studies often reported PAFs as a single point esti-
mates because of the difficulty in combining variances in
RRs and prevalence.7 10 In our study, we calculated not
only PAFs but also the associated confidence intervals,
which helps in the comparison of PAFs between sub-
groups or across years. For example, the difference in
PAFs between adiposity and smoking was only 3.7% in
2017 but the confidence intervals did not overlap giving
us greater certainly that the contribution of adiposity was
greater than that of smoking in that year. The confidence
intervals were wider for smoking than adiposity due to the
less precise estimates of RRs [15].
Comparing PAF estimates between studies is problem-
atic because prevalence differs between populations and
over time. Nonetheless, our estimates for smoking are
not dissimilar to a previous study, which reported that
19% of all deaths in 2005 were attributable to smoking
[7]. However, our study’s estimates of the PAF due to
adiposity were higher than previous estimates of 2 to
12% [22]. The meta-analysis from which we extracted
the RR for adiposity reported the mortality PAF for
Europe to be 13.5% [16], based on a prevalence of 33%
for overweight and 20% for obesity. In our study the
2017 prevalence of obesity in England and Scotland was
much higher at 30.3%. Differences in methodology may
also have contributed. For example, in that meta-analysis
obesity was treated as a single category whereas, in prac-
tice, the RR increases exponentially across obesity classes
I, II and III.
The Global Burden of Disease study ranked the top
risk factors in the United Kingdom based on disability
adjusted life years (DALYs) [23]. It reported that tobacco
use was still the top contributor to DALYs in 2017 even
though its contribution had fallen by 9.2% since 2007.
Over the same period, adiposity rose from fourth to
third rank, and its contribution increased by 7.6%. The
temporal trends are consistent with our findings. The
failure of adiposity to overtake smoking is likely to re-
flect a greater impact on disability from smoking than
adiposity; possibly due to its association with chronic
diseases, such as chronic obstructive pulmonary disease
(COPD), that impair functioning and wellbeing for a
sustained period of time.
Meaning of the study
Historical efforts to protect the public from the harms of
smoking have been successful. Adiposity now contrib-
utes to more deaths than smoking, which highlights the
need to prioritise strategies to address it, including
upstream policies and legislation [24], as well as down-
stream individual interventions. Middle and older age
groups and men, in particular, require support in help-
ing them to reduce their weight to a healthy level.
Unanswered questions and future research
The current study included the risk of only active and
former smoking. Given that vaping and e-cigarette use
are growing among long-term former smokers [25], and
passive smoking also contributes to mortality [26], future
studies should consider whether these specific legacies
of smoking require ongoing focus. Adiposity did not
outrank smoking among those under 45 years of age and
those finished school early when the surveys were
undertaken. However, birth cohort studies should be
undertaken in the future to fully understand changing
risk over time. The association of adiposity with mortal-
ity may differ by ethnicity and this might need to be
accounted for in future analysis. The combined associa-
tions of smoking and adiposity should be considered in
future individual-level studies, as there may be interac-
tions between them.
Conclusions
Since 2014, adiposity has contributed to more deaths in
England and Scotland than smoking. Prioritising smok-
ing has been successful at reducing its risk. Interventions
to reduce adiposity need to attract the same level of pri-
ority among policy makers, practitioners and public
health physicians.
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